Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?

Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience

“…One or two dysplasia lineages in BM occurred in 86.5% of patients. Mutations in ASXL1 , TET2 , SRSF2 , and RUNX1 were the most frequently noted in our cohort, similar to other published reports 22,23 …”

“…Similar to Ball et al (8%), it achieved 7.7% in the HMAs plus Vene group, whereas the HMAs plus ATO arm reached 11.1%. When analyzing the ORR, treatment with HMAs plus Vene resulted in an ORR of 53.8% in our cohort (n = 13), which is comparable to the response rates reported by Ball et al 23 (58.0%, n = 26) and Saliba et al 22 (50.0%, n = 6) which is lower than the results of Guillermo Montalban-Bravo et al 26 (67.0%, n = 27) that contained other treatment strategies. The research of Guillermo Montalban-Bravo et al 26 contained Vene combined cytotoxic agents and treatment strategies which prompted us to explore the diversification and optimization of Vene in the treatment of CMML in future research.…”

“…(8%), it achieved 7.7% in the HMAs plus Vene group, whereas the HMAs plus ATO arm reached 11.1%. When analyzing the ORR, treatment with HMAs plus Vene resulted in an ORR of 53.8% in our cohort ( n = 13), which is comparable to the response rates reported by Ball et al 23 . (58.0%, n = 26) and Saliba et al 22 .…”

“…With a follow‐up duration of 24 months, the HMAs plus Vene group demonstrated a longer median OS (not reached) compared to the durations reported by Ball et al 23 . and Saliba et al 22 .…”

“…Mutations in ASXL1, TET2, SRSF2, and RUNX1 were the most frequently noted in our cohort, similar to other published reports. 22,23 Vene is approved to treat elderly patients with newly diagnosed AML and high risk-MDS combined with either low-dose cytarabine or HMAs. 24,25 At present, few relevant studies are available.…”